NCT00450580已完成3 期
Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 212
- 试验地点
- 1
- 主要终点
- Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks
研究概览
简要总结
This is a Phase IIIB, 48 Week, multicentre, randomized, open-label, parallel group study comparing the safety and efficacy of fosamprenavir plus ritonavir 1400mg/100mg once-daily to fosamprenavir plus ritonavir 700mg/100mg twice-daily, both administered with abacavir/lamivudine 600mg/300mg once-daily in antiretroviral-naive HIV-1 infected adults. This study utilizes a group-sequential design with two stages: 1) an interim 24 week cohort analysis of approximately 200 subjects and 2) if study continuation criteria are met at this interim analysis, further enrolment of an additional 528 subjects, followed over a minimum of 48 weeks. The objectives of the study are to demonstrate 1) non-inferior antiviral activity of fosamprenavir/ritonavir 1400mg/100mg QD compared to fosamprenavir/ritonavir 700mg/100mg BID and 2) a superior fasting non-HDL lipid profile in subjects receiving fosamprenavir/ritonavir 1400mg/100mg QD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is ≥18 years of age.
- •Subject is antiretroviral-naïve (defined as having ≤14 days of prior therapy with any antiretroviral agent).
- •Subject has plasma HIV-1 RNA ≥1,000 copies/mL at screening.
- •Subject is willing and able to understand and provide written informed consent prior to participation in this study.
- •A female is eligible to enter and participate in the study if she is of:
- •Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal); or,
- •Child-bearing potential, has a negative pregnancy test (serum b-HCG) at screen and agrees to one of the following methods of contraception (any contraception method must be used consistently and correctly, i.e., in accordance with both the approved product label and the instructions of a physician):
- •Complete abstinence from intercourse from 2 weeks prior to administration of the investigational products, throughout the study, and for at least 2 weeks after discontinuation of all study medications
- •Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide). Hormonal contraception will not be permitted in this study
- •Any intrauterine device (IUD) with published data showing that the expected failure rate is <1% per year.
- •Sterilization (female subject or male partner of female subject). All subjects participating in the study should be counselled on the practice of safer sex.
- •Prior to randomization, subjects entering Stage 2 must have been screened and be negative for the HLA-B*5701 allele. Test may be performed by local laboratory and results must be available for source document verification according to local practices.
排除标准
- •Subject is in the initial acute phase of a CDC Clinical Category C infection at Baseline. Subjects may be enrolled provided they are receiving treatment for such infections and are clinically improving at the Baseline visit.
- •Subject is enrolled in one or more investigational drug protocols, which may impact HIV RNA suppression.
- •Subject is, in the opinion of the Investigator, unable to complete the study dosing period and protocol evaluations and assessments.
- •Subject is either pregnant or breastfeeding.
- •Subject suffers from any serious medical condition (such as pancreatitis, diabetes, congestive heart failure, cardiomyopathy or other cardiac dysfunction) which in the opinion of the Investigator would compromise the safety of the subject.
- •Subject has a pre-existing mental, physical, or substance abuse disorder which, in the opinion of the Investigator, may interfere with the subject's ability to comply with the dosing schedule and protocol evaluations and assessments.
- •Subject has a history of inflammatory bowel disease or intestinal malignancy, intestinal ischemia, malabsorption, or other gastrointestinal dysfunction, which, in the opinion of the Investigator, may interfere with drug absorption or render the subject unable to take oral medication.
- •Subject has any acute laboratory abnormality at screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study of an investigational compound. If subjects are found to have an acute Grade 4 laboratory abnormality at screening, this test may be repeated once within the 45-day screening window. Any verified Grade 4 laboratory abnormality would exclude a subject from study participation.
- •Subject has an estimated creatinine clearance < 50 mL/min via the Cockcroft-Gault method [Cockcroft, 1976]. This test may be repeated once within the 45-day screening window.
- •NOTE: Creatinine clearance should be estimated using the following formula:
- •For serum creatinine concentration in mg/dL:
- •For serum creatinine concentration in µmol/L:
- •Alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN) or hepatic impairment as determined by Child-Pugh Score ≥
- •Subject is receiving, or has received within 90 days prior to screen, any lipid lowering agent, including drugs from the following classes: HMG-CoA reductase inhibitors (statins), niacin, fibrates, bile acid sequestrants, and/or fish oil supplements. Subjects anticipated to require initiation of therapy with these agents within 12 weeks of Baseline are not eligible to participate.
- •Subject has received treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days prior to Screening, or has an anticipated need for these agents within the study period.
- •Subject has received treatment with an HIV-1 immunotherapeutic vaccine or any agents with documented activity against HIV-1 in vitro within 28 days prior Screening, or an anticipated need during the study.
- •Subjects who require treatment with any of the following medications within 28 days of commencement of investigational product, or an anticipated need during the study:
- •Amiodarone, astemizole, bepridil, cisapride, dihydroergotamine, ergonovine, ergotamine, flecainide, halofantrine, lidocaine, lovastatin, methylergonovine, midazolam, pimozide, propafenone, quinidine, simvastatin, terfenadine, triazolam.
- •Carbamazepine, dexamethasone, phenobarbital, phenytoin, primidone, rifampin, St Johns Wort (Hypericum perforatum), troglitazone.
- •Systemic interleukins or interferons.
- •Subject has a history of allergy to any of the investigational products or any excipients therein.
- •Subject has evidence of genotypic (as defined by the current ANRS AC-11 algorithm) resistance at screening or prior documented evidence of genotypic and/or phenotypic (above threshold for reduced susceptibility) resistance to amprenavir/ritonavir, abacavir or lamivudine.
- •Subjects recruited at sites in France will be excluded if:
- •The subject is not affiliated with or a beneficiary of a social security.
- •The subject has previously participated in an experimental drug and/or vaccine trial(s) within 60 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine - whichever is longer, prior to screening for the study.
- •The subject will participate simultaneously in another clinical study. Notwithstanding these minimum inclusion and exclusion criteria, investigators are urged to follow country specific guidelines where they exist when making decisions about subjects who are eligible for study participation.
研究组 & 干预措施
Arm A
Experimental
Fosamprenavir/ritonavir 1400mg/100mg QD + ABC/3TC FDC 600/300mg QD
干预措施: fosamprenavir/ritonavir (Drug)
Arm B
Active Comparator
Fosamprenavir/ritonavir 700mg/100mg BID + ABC/3TC FDC 600/300mg QD
干预措施: fosamprenavir/ritonavir (Drug)
结局指标
主要结局
Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks
时间窗: Week 48
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at week 48. The percentage of participants with HIV-1 RNA \<400 copies/mL at Week 48 was determined by the Time to Loss Of Virologic Response (TLOVR) algorithm.
次要结局
- Percentage of Participants With HIV-1 RNA <50 and >=50 Copies/mL by Visit Over 48 Weeks(Week 48)
- Number of Participants With HIV-1 RNA <400 Copies/mL (Primary Endpoint) at Week 48 Categorised by Baseline Viral Load, TLOVR Analysis(Week 48)
- Number of Participants With HIV-1 RNA <400 Copies/mL (Primary Endpoint) at Week 48 Categorised by Baseline CD4+ Count, TLOVR Analysis(Week 48)
- Change From Baseline in Non-HDL Cholesterol at Week 48(Week 48)
- Number of Protocol-defined Virological Failures With Genotypic and Phenotypic Resistance Changes(Time to virologic failure; Week 4 up to Week 48)
- Steady-state Levels of Amprenavir (APV) and Ritonavir (RTV) Ctau at Weeks 4, 12, and 24(Weeks 4, 12, and 24)
- Study Endpoints for a Subset of Subjects Receiving Study Drug Beyond 48 Weeks(Up to 60 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects. - MeritTreatment of HIV-1 infection.MedDRA version: 9.1Level: LLTClassification code 10008922Term: Chronic infection with HIVEUCTR2006-005579-16-DEGlaxoSmithKline Research & Development Ltd728
进行中（未招募）
不适用
Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects.Treatment of HIV-1 infectionMedDRA version: 9.1Level: LLTClassification code 10008922Term: Chronic infection with HIVEUCTR2006-005579-16-ESGlaxoSmithKline S.A. España728
进行中（未招募）
1 期
Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects.Treatment of HIV-1 infection.MedDRA version: 9.1Level: LLTClassification code 10008922Term: Chronic infection with HIVEUCTR2006-005579-16-FRGlaxoSmithKline Research & Development Ltd
进行中（未招募）
不适用
Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects.Treatment of HIV-1 infection.MedDRA version: 9.1Level: LLTClassification code 10008922Term: Chronic infection with HIVEUCTR2006-005579-16-BEGlaxoSmithKline Research & Development Ltd728
进行中（未招募）
1 期
Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects.EUCTR2006-005579-16-GBGlaxoSmithKline Research & Development Ltd